Medigene participates at five upcoming international conferences

Medigene AG / Medigene participates at five upcoming international conferences . Processed and transmitted by Nasdaq OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Martinsried/Munich, 3 August 2016. Medigene AG (MDG1, Frankfurt, Prime Standard) announces its participation at five upcoming science, investment and business development conferences:

•  CAR-TCR Summit

Date: 13 - 15 September 2016
Location: Boston, USA
CEO/CSO Prof. Dolores Schendel will give a talk on 14 September on the topic: "The ABC's of Adoptive T Cell Therapy Using Optimal-Affinity Natural TCRs Specific for Hematological Malignancies and Solid Tumors".

• Baader Investment Conference

Date: 20 - 22 September 2016
Location: Munich, Germany
Medigene's Senior Vice President Corporate Development, Dr. Dr. Olav Zilian, will give a corporate presentation on 21 September.

• Phacilitate Leaders Europe

Date: 21 - 22 September 2016
Location: Berlin, Germany
Medigene's Senior Vice President Medical Affairs & CMO, Dr. Kai Pinkernell, will present on 22 September 2016 on: "What improvements can second and third generation CAR and TCR-based immunotherapies offer in terms of both safety and persistence of response?"

• Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival

Date: 25 - 28 September 2016
Location: New York, USA
Medigene will present a poster on 25 and 26 September with the title: "Method for molecular characterization of antigens, epitopes and T cell receptors for adoptive CD4 immunotherapy".

• European Business Development Conference

Date: 27 - 28 September 2016
Location: Frankfurt, Germany

Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative, complementary treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development.  MediGene concentrates on the development of personalized T cell-based immunotherapies.

For more information, please visit www.medigene.com

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene^® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Contact Medigene AG
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01,
email: investor@medigene.com

In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.

--- End of Message ---

Medigene AG
Lochhamer Strasse 11 Martinsried / München Germany

WKN: A1X3W0;ISIN: DE000A1X3W00;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;